|
|
| (23 intermediate revisions by 3 users not shown) |
| Line 2: |
Line 2: |
| | <html> | | <html> |
| | | | |
| − | <h1>Introduction</h1> | + | <h1>Introduction to our Human Practices</h1> |
| | | | |
| − | | + | <p> In our work with Human Practices we have focused on making safety choices based on feedback from experts, integrating experts advice on protein production for space purposes and exploring the reasons for colonizing Mars by making a report. The report is made in collaboration with the other danish iGEM team coming from the Technical University of Denmark and with the iGEM team coming for the University of Exeter. We have also engaged in skill-sharing between iGEM 'ers both with a <a href="https:// 2018. igem. org/ Team: UCopenhagen/ Events_Attended"> workshop</ a> at the European meet- up and with beginner friendly < a href="https:/ /2018. igem. org/ Team: UCopenhagen/Wiki_how_tos" >guides</ a> about wikipages, which drew alot of attention to our <a href="https:// medium.com/igem-copenhagen"> Medium Blog</ a></p> |
| − | <p> | + | |
| − | We have aimed towards incorporating Human Practice-thinking into as many aspects and phases of our work as possible. Therefore we did already in the choosing of our project decide some factors that we found important to take into consideration when choosing our project: First and foremost we wanted to make something that was not going to interfere with nature or human bodies. We wanted to make a product that would make a positive difference in the world taking into account certain societal factors such as safety and usability, avoiding harm to the environment, and considering ethical downsides.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | In order to find the right idea, we met up with different people and the team members spoke with their families, friends, peers and professors in order to find ideas on wich problems we could potentially solve with our project. We spent weeks discussing up-to-date topics such as microplastic pollution, radiation, antibiotic resistance, coculture and much more. You can read more about our choosing process here ….
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | We have also been concerned about safety at an early stage and has therefore contacted the Danish Center for Biopreparedness and biosafety in order to get their evaluation on our idea. Besides from that we had an extensive dialogue with the iGEM safety council and our internal safety officers. You can read more about their evaluation and our safety choices based on the feedback here ….
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | After choosing our project, we spoke with some different experts in the protein and space medicine field about which proteins would be relevant for space travel. We got a lot of interesting input and it had a big impact of how we now perceive the uses of our products and the problems it can potentially solve. You can read more about the experts and our integration of their input here …
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | When we were at Nordic iGEM conference in Lund, we noticed that we had a lot in common with the other Danish iGEM team, DTU Biobuilders. We decided to propose for a collaboration with DTU and at the same time Exeter asked us about collaborating. We ended up collaborating all three together. You can read more about our collaboration with DTU and Exeter here...
| + | |
| − | </p>
| + | |
| − | | + | |
| − | | + | |
| − | <h1>The (journey of) choosing our project</h1>
| + | |
| − | | + | |
| − | | + | |
| − | <p>
| + | |
| − | iGEM team copenhagen is a very mixed group of people, both in terms of age, gender, nationality and competencies - a diversity that we have embraced and taking into account by fx making a team contract that states expectations for team members. We were assembled in March and spend our first day together competing in building towers from spaghetti and marshmallows. | + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | After the spaghetti we went straight to core values - a continues discussion taking place for several weeks. We decided that we wanted to make a product that was useful, and we wanted to investigate all potential downsides before making a choice - that was and is the most important values for all of us. We also wanted to have an almost flat team structure and to make a team contract in order to know what to expect from each other. You can read our team contract here…
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | We spoke with different people in order to learn about current problems that could be solved with synthetic biology. To get initial inspiration we met up with previous team members from iGEM teams at UCPH in order to discuss their projects and what kind of problems they were trying to solve. We asked friends, and family and got inspiration from different professors at the department for synthetic biology at UCPH.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | At the end one meeting proved to be exceptionally fruitful for us, and that was the meeting with Astrobiologist, Lynn Rothschild. Rothschild has collaborated with previous iGEM Copenhagen teams as a supervisor for the iGEM team at Brown university. One early spring day this year she visited Copenhagen and found time to meet up with us and made a very interesting lecture about subjects such as upmass and self sufficiency. To make a long story short, Rothschild inspired us to explore problems in space further.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | When one team member came into the office and had as an act of procrastination read about the Salmonella bacterium, the idea of using the injectisome to produce and release proteins was born. Many team members were immediately amazed with the idea, but we decided that we had to think it to an end before jumping into the lab.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Therefore we developed on three different ideas in parallel and did extensive research on societal impact of all of them. We learned a lot from our discussions of the three different ideas, and ended up deciding to choose the injectisome idea because it is not releasing gmo into nature, it is potentially beneficial both on earth and in space, it might in the future be a greener and more efficient method of producing protein, without taking any risks health wise or doing harm on any ecosystems.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | (Pictures: Spaghetti teambuilding, Lynn + team)
| + | |
| − | </p>
| + | |
| − | | + | |
| − | <h1>Collaboration with DTU and Exeter </h1>
| + | |
| − | | + | |
| − | | + | |
| − | <p>
| + | |
| − | We noticed our common interests with DTU quite early. Already at the Nordic iGEM Conference in june, we were amazed by the DTU teams presentation and immediately felt the urge to work together. We spoke about how their ideas about using fungi for building on Mars, matched our idea about protein production on Mars - our common interest in exploring Mars was very obvious to us from the beginning. When we got home we decided to prepare ourselves for the proposal and contacted DTU to tell them how beneficial it would be to all of us if we worked together - come on, we're almost neighbors and we are working with the same topic?
| + | |
| − | </p> | + | |
| − | <p>
| + | |
| − | In the meantime we got a request from Exeter asking if we would like to collaborate with them, and who could say no to that proposal? We couldn't, especially not since Exeter are working with a super interesting project about making oxygen with help from already present gasses and modified bacteria. Awesome, we thought. But what about DTU?
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Luckily DTU said yes (or more accurately: "Yaaaas!!"), when we presented our idea of collaborating all three together.
| + | |
| − | </p> | + | |
| − | <p>
| + | |
| − | When we decided to collaborate we didn't really have a plan. Brainstorming was a big part of our first Skype meetings, and because of our early start, our discussions managed to shape parts of each others Human Practice projects. We especially discussed how unusual it was for space related igem teams to question space travel ethically, even though there are lots of obvious questions to ask. We decided that we would like to explore the questions further and found especially the history of colonization, the arguments for and against Mars colonization and the ethics of colonization interesting and worthy of further exploration. We decided that we would make a report with the topic "Why colonize Mars?", where we would first analyze historical reasons for colonizing land, then analyze the main arguments in the public debate about Mars colonization and at the end discus our results in a ethical context.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | We also contacted the Planetarium in Copenhagen in order to ask them for the possibility of giving a talk at one of their events, but instead of that they offered us a booth at one of the major cultural event nights in Copenhagen. We were very happy about that and contacted DTU immediately to hear if they would be interested in participating and having the booth together - Luckily they were very interested and we decided to extend our collaboration so it included the event at . You can read more about our collaboration at the Planetarium event here and find our report Here (link)
| + | |
| − | </p> | + | |
| − | | + | |
| − | <h1>Choosing a protein</h1>
| + | |
| − | <h2>Integrated Human Practice</h2>
| + | |
| − | | + | |
| − | | + | |
| − | <p>
| + | |
| − | <strong>In parallel with developing our project we have been speaking with several experts within the field of health and space medicine</strong>. They have contributed with very valuable inputs for our project. One limit for choosing a protein for now is that protein therapeutics for improving the human conditions during space exploration isn't very established yet. Therefore, we have made a list of useful proteins that we theoretically should be able to produce with our system.
| + | |
| − | </p> | + | |
| − | <p>
| + | |
| | | | |
| − | </p> | + | <h2>Integration of experts’ input on protein choice for space health</h2> |
| − | <h3>Proteins of interest for space exploration</h3> | + | <p>We reached out to experts within the field of health in space in order to learn more about the main problems of health in space.</p> |
| | + | <p>Our findings has greatly impacted the purpose with the project, as it has: </p> |
| | + | <ul> |
| | + | <li>Helped us understand which problems we can solve and how</li> |
| | + | <li>Helped us conclude on a list of proteins that would be ideal for space travel related health issues</li> |
| | + | </ul> |
| | + | <p>You can read more about the experts and our integration of their input <a href="https://2018.igem.org/Team:UCopenhagen/Choice_of_Protein">here</a>.</p> |
| | | | |
| − | | + | <h2>Safety choices and expert evaluations</h2> |
| − | <h4>IgG stan</h4> | + | <p>In order to make sure that our system for protein production is safe to use, and in order to carry out our own laboratory work as responsible as possible, we have been in extensive dialogue with safety experts. We have:</p> |
| − | | + | <ul> |
| − | | + | <li>Evaluated the dual-use risk of our system with the Danish Centre for Biosecurity and Biopreparedness</li> |
| − | <p> | + | <li>Implemented needed extra safety precautions including required lab coats, eye, nose and mouth protection and created a buffer zone</li> |
| − | IgG stan is a collection of IgG antibodies from human donors. The IgG stan is therefore a collection of antibodies with different specificity. IgG is very useful for presenting antigens to the immune system and can therefore function as a booster of the activity of the immune system of the host. Data shows that the immune system is dysregulated under microgravity and therefore it might be interesting to produce proteins that help improve the activity of the immunesystem [1]. We were pointed in this direction when speaking with Virginia Wotring.
| + | <li>Chosen to work with a non-pathogenic bacterial strain with inducible injectisome</li> |
| − | </p> | + | <li>Worked only with plant- or artificial membranes </li> |
| − | <p> | + | <li>Integrated safety considerations in our choice of user and design of the chamber</li> |
| − |
| + | </ul> |
| − | </p> | + | <p>You can read more about our work with safety, the Dual-use evaluation from the Danish center biosecurity and biopreparedness and our safety choices based on the feedback <a href="https://2018.igem.org/Team:UCopenhagen/Safety">here</a>. |
| − | <p>
| + | |
| − | Immune modulators
| + | |
| − | </p> | + | |
| − | <p> | + | |
| − | As mentioned above the immune system is believed to be dysregulated during microgravity [1]. Therefore, other proteins that affect the immunesystem could be interesting to produce with our system. This could both be cytokines, interleukines and other immune regulatory proteins. We were also pointed in this direction by Virginia Wotring.
| + | |
| − | </p> | + | |
| − | <p> | + | |
| − |
| + | |
| − | </p> | + | |
| − | <p> | + | |
| − | Granulocyte Colony Stimulating Factor (G-CSF)
| + | |
| − | </p> | + | |
| − | <p> | + | |
| − | Radiation in space is markedly higher anda part of acute radiation syndrome is hematopoietic syndrome. This syndrome is characterized by a reduction in the number of neutrophils. Neutrophils are an important part of the innate immune system and as the number of neutrophils decrease the probability of infections increase. G-CSF promote the differentiation of neutrophils and can therefore be a possible countermeasure to low neutrophil cell count [2][3]. <strong> </strong>We were also pointed in this direction by Virginia Wotring.
| + | |
| − | </p> | + | |
| − | <p> | + | |
| − |
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Insulin like growth factor 1(IGF-1)
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Has previously been addressed as a potential therapeutic protein to prevent the muscle atrophy [4]. The idea being that IGF-1 acts directly on the target tissue promoting growth. We had thought about producing IGF-1 ourself and discussed this with Jon Scott who thought that it might be very interesting and useful for long term missions to combine these anabolic proteins with exercise in space.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − |
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Growth hormone (GH)
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Growth hormone has both long term and short term effects. The short term effects are diabetogenic while the long term effects promotes tissue growth especially muscle and bone. The long term effects of GH are mediated by IGF-1[5][6]<strong>. </strong> Therefore both IGF-1 and GH are very closely linked, and whether to use one instead of the other depends on the therapeutical context. We had thought about producing GH ourself but discussed it with Jon Scott who thought that it might be very interesting to combine these anabolic proteins with exercise in space.
| + | |
| − | </p> | + | |
| − | <p>
| + | |
| − |
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Parathyroid hormone (PTH)<strong> </strong>
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Parathyroid hormone is produced in parathyroid gland and is secreted in response to low blood calcium concentration. PTH activate the osteoclasts and thereby promote bone resorption and release of calcium and phosphate into the circulation. PTH also promotes secretion of phosphate in the kidney, thereby elevating the concentration of free calcium ions. Despite this PTH also has anabolic effects on bone and is currently used as a osteoporosis drug [7]which makes PTH a very interesting protein for us to produce.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − |
| + | |
| − | </p>
| + | |
| − | <p> | + | |
| − | Antibody/ single domain antibody
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Almost all the experts we have talked to suggested us to produce antibodies, because antibodies are useful for a lot of different things. Our main idea as it is right now it to produce antibodies for detection of different molecules, this could be used both for differential diagnosis of astronauts but also for research purposes and help in a lot of different research purposes in space for instance enlightening what happens to the human body under microgravity. We have looked into which alternatives there is to normal antibody and found that there exists a single domain antibody that might be easier to produce and are as specific as the human one[8].
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − |
| + | |
| | </p> | | </p> |
| − | <h3>Requirements for production with our system</h3>
| |
| | | | |
| | + | <h2>Collaboration - Why colonize Mars?</h2> |
| | + | <p>We have collaborated with the other Danish iGEM team from the Technical University of Denmark, <a href="https://2018.igem.org/Team:DTU-Denmark"><i>Hyphae hackers</i></a>, and the iGEM team from the University of Exeter, <a href="https://2018.igem.org/Team:Exeter"><i>Project perchlorate</i></a>. |
| | + | Together we have:</p> |
| | + | <ul> |
| | + | <li>Had an extensive dialogue from early in the process</li> |
| | + | <li>Made a interdisciplinary report on Mars colonization in which we together examine the motivations for Mars colonization, and the bioethical concerns of bringing humans to Mars. You can read our report <a href="https://2018.igem.org/Team:UCopenhagen/HP_rapport">here</a> </li> |
| | + | </ul> |
| | + | <p>We have furthermore collaborated with Hyphae hackers on an event held in the Tycho Brahe Planetarium in Copenhagen. Read about the event <a href="https://2018.igem.org/Team:UCopenhagen/Public_Engagement">here</a>. |
| | + | You can read more about our collaboration with DTU and Exeter <a href="https://2018.igem.org/Team:UCopenhagen/Why_Colonize_Mars">here</a>.</p> |
| | | | |
| | + | <h2>Theraputic Proteins</h2> |
| | <p> | | <p> |
| − | The principle on which our system works allows for extremely pure protein to be obtained, but at the other hand presents limitations concerning complexity of the proteins that can be produced. One limitation is folding of the proteins, once the protein of interest is secreted across the membrane it needs to be able to fold more or less by itself in the conditions of the buffer. This means that smaller and simpler proteins are better to produce with our system given that they are better at folding on their own. How big this folding challenge will be will become clearer when we have data on production of protein with our system. For now we have spoken with Michael Hecht at the European iGEM meetup who suggested we tried to produce his fusion proteins that were better at self-folding. If they work well we could try using his technique for protein production with our system and our protein of interest.
| + | For a lot of people, the phrase <em>theraputic proteins</em> is new and unknown territory. We have written an article introducing the concept and it's historical genisis. You can read the article |
| − | </p> | + | |
| − | <p>
| + | |
| − | Because we produce our proteins using <em>E. coli </em>there are some limitations as to the posttranslational modification (PTM) of the proteins we intend to produce, for instance it is not possible to produce glycosylated proteins. PTM are more characteristic for eukaryotic systems, and this fact further complicates protein production, since some PTMs can't be performed in prokaryotic cells.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | The protein to produce with our system should therefore be as simple as possible, able to fold by itself, have a minimum number of post-translational modifications and be relatively stable.
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − |
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | Based on these criteria we have tried to make a review of the feasibility of producing the proteins that might be interesting for space travel.
| + | |
| − | </p>
| + | |
| − | | + | |
| − | <table>
| + | |
| − | <tr>
| + | |
| − | <td><strong>Protein</strong>
| + | |
| − | </td>
| + | |
| − | <td><strong>Complexity</strong>
| + | |
| − | </td>
| + | |
| − | <td><strong>Structure (obtained from Uniprot)</strong>
| + | |
| − | </td>
| + | |
| − | <td><strong>Uniprot code</strong>
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | <tr>
| + | |
| − | <td><strong>PTH</strong>
| + | |
| − | </td>
| + | |
| − | <td>66,3kDa
| + | |
| − | <p>
| + | |
| − | 3 disulfide bonds, 4 glycosilations, 1 N-glycosilation
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | <td>Q03431
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | <tr>
| + | |
| − | <td><strong>Camel antibody</strong>
| + | |
| − | </td>
| + | |
| − | <td> <span style="text-decoration:underline;">14,0 kDa</span>
| + | |
| − | <p>
| + | |
| − | <span style="text-decoration:underline;">1 disulfide bond</span>
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | <td>A2KD59
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | <tr>
| + | |
| − | <td><strong>IGF-1</strong>
| + | |
| − | </td>
| + | |
| − | <td>21,8 kDa
| + | |
| − | <p>
| + | |
| − | 3 disulfide bonds
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | <td>P05019
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | <tr>
| + | |
| − | <td><strong>G-CSF</strong>
| + | |
| − | </td>
| + | |
| − | <td>22,3 kDa
| + | |
| − | <p>
| + | |
| − | 2 disulphide bonds and glycosylation
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | <td>P09919
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | <tr>
| + | |
| − | <td><strong>Growth hormone</strong>
| + | |
| − | </td>
| + | |
| − | <td>2 disulfide bonds and 4 modified residues
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | <td>P01241
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | <tr>
| + | |
| − | <td><strong>Antibody (IgG)</strong>
| + | |
| − | </td>
| + | |
| − | <td>150 <a href="https://en.wikipedia.org/wiki/KDa">kDa</a> <a href="https://www.ncbi.nlm.nih.gov/books/NBK27144/">(a)</a>, presence of disulfide bonds, too complex
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | <td>
| + | |
| − | </td>
| + | |
| − | </tr>
| + | |
| − | </table>
| + | |
| | | | |
| | + | <a href="https://2018.igem.org/Team:UCopenhagen/Theraputic_Proteins">here</a> </p> |
| | | | |
| | <p> | | <p> |
| − | No matter which protein we choose to produce we will need to optimize the conditions. How important the theoretical limitations we present here are, will be further unveiled upon investigation and experiments.
| + | Our product is not the only way of purifying proteins. By speaking with experts we have made an evaluation of how well our system works, compared to other methods. You can read more about this |
| − | </p>
| + | |
| − | <p>
| + | |
| − |
| + | |
| − | </p>
| + | |
| − | <p>
| + | |
| − | <strong>To sum up, we propose to use our system for production of IGF-1, PTH, G-CSF and camelid antibody during long lasting space missions</strong>. This decision is first of all based on our interviews with experts within the field of space medicine. Based on their opinions we have further looked into how easy the different proteins would be to produce with our system (looking into PTM, size, the litterature etc). It has been very important for development of our project to have the possibility to speak with experts such as Virginia Wotring, Jon scott, Eva Horn Møller and Jørgen Sauer and we have very much incorporated their inputs into the very core of our project.
| + | |
| − | </p>
| + | |
| − | | + | |
| − | <p>
| + | |
| | | | |
| − | [1] B. E. Crucian <em>et al.</em>, "Immune system dysregulation during spaceflight: Potential countermeasures for deep space exploration missions," <em>Front. Immunol.</em>, vol. 9, no. JUN, pp. 1–21, 2018.
| + | <a href="https://2018.igem.org/Team:UCopenhagen/Protein_Production_System">here</a> |
| | </p> | | </p> |
| − | <p>
| |
| | | | |
| − | [2] E. Seedhouse, <em>Space Radiation and Astronaut Safety</em>. .
| |
| − | </p>
| |
| − | <p>
| |
| | | | |
| − | [3] M. P. Mac Manus, D. McCormick, A. Trimble, and W. P. Abram, "Value of granulocyte colony stimulating factor in radiotherapy induced neutropenia: Clinical and laboratory studies," <em>Eur. J. Cancer</em>, vol. 31, no. 3, pp. 302–307, Jan. 1995.
| |
| − | </p>
| |
| − | <p>
| |
| | | | |
| − | [4] Y.-H. Song, J. L. Song, P. Delafontaine, and M. P. Godard, "The therapeutic potential of IGF-I in skeletal muscle repair.," <em>Trends Endocrinol. Metab.</em>, vol. 24, no. 6, pp. 310–9, Jun. 2013.
| |
| − | </p>
| |
| − | <p>
| |
| − |
| |
| − | [5] C. S. Leach, N. M. Cintron, and J. M. Krauhs, "Metabolic changes observed in astronauts," <em>J.Clin.Pharmacol.</em>, vol. 31, no. 0091–2700 (Print), pp. 921–927, 1991.
| |
| − | </p>
| |
| − | <p>
| |
| − |
| |
| − | [6] W. Boron and E. Boulpaep, <em>Medical Physiology</em>. 2008.
| |
| − | </p>
| |
| − | <p>
| |
| − |
| |
| − | [7] D. Aslan <em>et al.</em>, "Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans," <em>Scand. J. Clin. Lab. Invest.</em>, vol. 72, no. 1, pp. 14–22, Feb. 2012.
| |
| − | </p>
| |
| − | <p>
| |
| − |
| |
| − | [8] M. M. Harmsen and H. J. De Haard, "Properties, production, and applications of camelid single-domain antibody fragments.," <em>Appl. Microbiol. Biotechnol.</em>, vol. 77, no. 1, pp. 13–22, Nov. 2007.
| |
| − | </p>
| |
| | | | |
| | | | |
| | </html> | | </html> |
| | {{UCopenhagen/Footer}} | | {{UCopenhagen/Footer}} |
Introduction to our Human Practices
In our work with Human Practices we have focused on making safety choices based on feedback from experts, integrating experts advice on protein production for space purposes and exploring the reasons for colonizing Mars by making a report. The report is made in collaboration with the other danish iGEM team coming from the Technical University of Denmark and with the iGEM team coming for the University of Exeter. We have also engaged in skill-sharing between iGEM'ers both with a workshop at the European meet-up and with beginner friendly guides about wikipages, which drew alot of attention to our Medium Blog
Integration of experts’ input on protein choice for space health
We reached out to experts within the field of health in space in order to learn more about the main problems of health in space.
Our findings has greatly impacted the purpose with the project, as it has:
- Helped us understand which problems we can solve and how
- Helped us conclude on a list of proteins that would be ideal for space travel related health issues
You can read more about the experts and our integration of their input here.
Safety choices and expert evaluations
In order to make sure that our system for protein production is safe to use, and in order to carry out our own laboratory work as responsible as possible, we have been in extensive dialogue with safety experts. We have:
- Evaluated the dual-use risk of our system with the Danish Centre for Biosecurity and Biopreparedness
- Implemented needed extra safety precautions including required lab coats, eye, nose and mouth protection and created a buffer zone
- Chosen to work with a non-pathogenic bacterial strain with inducible injectisome
- Worked only with plant- or artificial membranes
- Integrated safety considerations in our choice of user and design of the chamber
You can read more about our work with safety, the Dual-use evaluation from the Danish center biosecurity and biopreparedness and our safety choices based on the feedback here.
Collaboration - Why colonize Mars?
We have collaborated with the other Danish iGEM team from the Technical University of Denmark, Hyphae hackers, and the iGEM team from the University of Exeter, Project perchlorate.
Together we have:
- Had an extensive dialogue from early in the process
- Made a interdisciplinary report on Mars colonization in which we together examine the motivations for Mars colonization, and the bioethical concerns of bringing humans to Mars. You can read our report here
We have furthermore collaborated with Hyphae hackers on an event held in the Tycho Brahe Planetarium in Copenhagen. Read about the event here.
You can read more about our collaboration with DTU and Exeter here.
Theraputic Proteins
For a lot of people, the phrase theraputic proteins is new and unknown territory. We have written an article introducing the concept and it's historical genisis. You can read the article
here
Our product is not the only way of purifying proteins. By speaking with experts we have made an evaluation of how well our system works, compared to other methods. You can read more about this
here
